Audentes Therapeutics, Inc. (NASDAQ:BOLD) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.
On May 11, 2017, the Company reported its financial results for
the quarter ended March 31, 2017. A copy of the press release
issued by the Company is furnished as Exhibit 99.1 to this
report.
The information furnished with Item 2.02 of this report,
including Exhibit 99.1, shall not be deemed filed for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended
(the Exchange Act), or otherwise subject to the liabilities of
that section, nor shall it be deemed incorporated by reference
into any other filing under the Exchange Act or under the
Securities Act of 1933, as amended, except as expressly set forth
by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
|
Exhibit Number |
Description |
|
99.1 |
Press release dated May 11, 2017. |
About Audentes Therapeutics, Inc. (NASDAQ:BOLD)
Audentes Therapeutics, Inc. is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT). The Company’s subsidiary is Audentes Therapeutics UK Ltd. As of September 30, 2016, the Company had not generated any revenues. Audentes Therapeutics, Inc. (NASDAQ:BOLD) Recent Trading Information
Audentes Therapeutics, Inc. (NASDAQ:BOLD) closed its last trading session up +0.43 at 15.09 with 166,119 shares trading hands.